Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 28% ± 12% | |
microglial cell | 11 studies | 31% ± 9% | |
GABAergic neuron | 10 studies | 43% ± 24% | |
glutamatergic neuron | 9 studies | 44% ± 24% | |
macrophage | 8 studies | 29% ± 11% | |
interneuron | 6 studies | 43% ± 21% | |
endothelial cell of lymphatic vessel | 6 studies | 27% ± 6% | |
mast cell | 6 studies | 28% ± 12% | |
oligodendrocyte precursor cell | 5 studies | 20% ± 3% | |
monocyte | 5 studies | 26% ± 9% | |
neuron | 4 studies | 25% ± 6% | |
GABAergic interneuron | 3 studies | 37% ± 4% | |
retinal ganglion cell | 3 studies | 29% ± 7% | |
epithelial cell | 3 studies | 19% ± 4% | |
cardiac muscle cell | 3 studies | 24% ± 2% | |
dendritic cell | 3 studies | 19% ± 2% | |
myeloid cell | 3 studies | 27% ± 2% | |
endothelial cell of vascular tree | 3 studies | 21% ± 6% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 20% ± 1% | |
alveolar macrophage | 3 studies | 35% ± 8% | |
goblet cell | 3 studies | 28% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 10 studies | 34% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 1418.32 | 966 / 966 | 97% | 25.36 | 510 / 527 |
brain | 97% | 729.85 | 2550 / 2642 | 94% | 8.40 | 666 / 705 |
breast | 100% | 596.86 | 458 / 459 | 87% | 12.11 | 969 / 1118 |
skin | 95% | 800.16 | 1725 / 1809 | 89% | 18.81 | 419 / 472 |
bladder | 100% | 498.29 | 21 / 21 | 75% | 14.86 | 379 / 504 |
stomach | 78% | 209.83 | 280 / 359 | 93% | 21.33 | 267 / 286 |
esophagus | 92% | 476.29 | 1332 / 1445 | 78% | 10.82 | 142 / 183 |
adrenal gland | 87% | 253.76 | 224 / 258 | 77% | 18.10 | 178 / 230 |
kidney | 93% | 295.78 | 83 / 89 | 70% | 5.69 | 631 / 901 |
lung | 100% | 808.29 | 578 / 578 | 59% | 5.25 | 685 / 1155 |
thymus | 97% | 314.02 | 633 / 653 | 53% | 2.89 | 320 / 605 |
uterus | 99% | 439.31 | 169 / 170 | 49% | 4.99 | 227 / 459 |
prostate | 90% | 249.34 | 221 / 245 | 20% | 0.83 | 101 / 502 |
adipose | 100% | 761.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1211.98 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.84 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 25.40 | 79 / 80 |
pancreas | 12% | 21.96 | 39 / 328 | 85% | 9.92 | 152 / 178 |
peripheral blood | 97% | 1474.31 | 902 / 929 | 0% | 0 | 0 / 0 |
heart | 86% | 210.38 | 743 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 80% | 242.18 | 1067 / 1335 | 0% | 0 | 0 / 0 |
ovary | 37% | 80.37 | 67 / 180 | 38% | 2.84 | 162 / 430 |
tonsil | 0% | 0 | 0 / 0 | 53% | 3.18 | 24 / 45 |
lymph node | 0% | 0 | 0 / 0 | 52% | 2.59 | 15 / 29 |
muscle | 39% | 69.64 | 316 / 803 | 0% | 0 | 0 / 0 |
liver | 11% | 18.35 | 24 / 226 | 17% | 1.53 | 68 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010025 | Biological process | wax biosynthetic process |
GO_0035336 | Biological process | long-chain fatty-acyl-CoA metabolic process |
GO_0005778 | Cellular component | peroxisomal membrane |
GO_0005777 | Cellular component | peroxisome |
GO_0102965 | Molecular function | alcohol-forming long-chain fatty acyl-CoA reductase activity |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0080019 | Molecular function | alcohol-forming very long-chain fatty acyl-CoA reductase activity |
Gene name | FAR2 |
Protein name | Fatty acyl-CoA reductase (EC 1.2.1.84) Fatty acyl-CoA reductase 2 (EC 1.2.1.84) (Male sterility domain-containing protein 1) |
Synonyms | MLSTD1 |
Description | FUNCTION: Catalyzes the reduction of saturated but not unsaturated C16 or C18 fatty acyl-CoA to fatty alcohols. A lower activity can be observed with shorter fatty acyl-CoA substrates . It may play a role in the production of ether lipids/plasmalogens and wax monoesters which synthesis requires fatty alcohols as substrates (By similarity). . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . |
Accessions | ENST00000547759.2 ENST00000686305.1 H0YIE0 H0YHP1 ENST00000686419.1 A0A8I5KVC4 A0A8I5KXF4 A0A8I5KUM2 ENST00000182377.8 [Q96K12-1] ENST00000691273.1 ENST00000536681.8 [Q96K12-1] ENST00000690162.1 [Q96K12-2] ENST00000693163.1 ENST00000692223.1 F8VPF2 ENST00000551193.2 A0A8I5KS86 ENST00000552137.1 F8VX60 A0A8I5KQJ4 ENST00000547116.5 [Q96K12-2] Q96K12 ENST00000551451.6 |